Company intelligence / Profile preview

Tox Path

Leiden, South Holland, Netherlands

Ownership: Private
Employees: ~30
Development stage: Other

Overview

ToxPath is a contract research organization (CRO) specializing in mechanistic toxicity testing and genetic toxicology. The company is best known for its proprietary ToxTracker platform, a suite of mammalian cell-based reporter assays that provide detailed insights into the mode of action of genotoxic and non-genotoxic compounds. ToxPath supports the pharmaceutical, chemical, and consumer product industries by helping to identify potential safety risks early in the drug development process. In 2021, the company was acquired by Charles River Laboratories to enhance their discovery and safety assessment capabilities.

Industry: Contract Research Organization

Beyond the preview

Go deeper on Tox Path.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tox Path.

Explore the full profile